ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer will license its COVID-19 antiviral, PF-07321332, to the Medicines Patent Pool (MPP), which will make the drug available to generic-drug makers in low- and middle-income countries, assuming it is approved. Merck & Co. struck a similar deal with MPP in October for its investigational antiviral, molnupiravir. Pfizer says lower-income countries will pay a not-for-profit price.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X